ATX01, a new topical treatment for chemotherapy-induced peripheral neuropathy, will be investigated in a phase 2 trial. Researchers recently initiated a phase 2 clinical trial evaluating ATX01 ...
A French-American research team discovered that the investigational compound Carba1 may prevent chemotherapy-induced peripheral neuropathy (CIPN) in preclinical models. According to a study published ...
Peripheral neuropathy (PN) is a dose-limiting side effect of chemotherapeutic and antibody drug conjugate (ADC) treatment which significantly impacts patients’ quality of life. Despite a high clinical ...
Chemotherapy-induced peripheral neuropathy (CIPN) – nerve pain, tingling, or numbness in the hands or feet – is a common side effect of certain cancer treatments, including two drugs frequently used ...
More than half of patients with breast cancer who receive chemotherapy may experience moderate to very severe neuropathy more ...
A University of Arizona Comprehensive Cancer Center researcher received a $2.4 million National Cancer Institute grant to develop a noninvasive, confocal microscope to examine nerve endings of cancer ...
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer Chemotherapy-induced peripheral neuropathy (CIPN) is a ...
Researchers have identified another potential gene therapy for treating chronic pain, this time by indirectly targeting a key sodium ion channel. In a study published July 27 in Proceedings of the ...
Halneuron, a NaV 1.7 sodium channel inhibitor, is being tested for chemotherapy-induced neuropathic pain, offering a potential opioid alternative. Previous trials showed Halneuron significantly ...
Growing prevalence of diabetes and neurological disorders accelerates innovation in neuropathy treatment landscape.Austin, United States, April 02, 2026 (GLOBE NEWSWIRE) -- As per SNS Insider, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results